MarketPulse

genomics

5 articles
The Motley FoolThe Motley Fool··Rick Munarriz

Cathie Wood's ARK Funds Buy the Dip in Shopify, Intellia, GeneDX

ARK Invest added positions in Shopify, Intellia Therapeutics, and GeneDX after significant stock declines, signaling Wood's conviction in long-term potential despite near-term headwinds.
SHOPWGSWGSWWNTLAstock declinegrowth stocks
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Omics-Based Clinical Trials Market to Nearly Double to $47.78B by 2030

Omics clinical trials market grows 8.8% annually from $31.71B in 2025 to $47.78B by 2030, driven by personalized medicine demand and AI advances.
PFELLYILMNRHHBYTMO+4personalized medicinereal-world evidence
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Drug Development Services Market Set to Double to $50B by 2030

Drug development services market projected to reach $50.26B by 2030 from $28.09B in 2025, driven by AI adoption, personalized medicine, and emerging market expansion.
CRLIQVLZAGYLHWUXAYregulatory complianceclinical trials
The Motley FoolThe Motley Fool··Rick Munarriz

Cathie Wood's Selective Week: ARK Invest Adds Only 3 Stocks Amid Market Volatility

ARK Invest bought just three stocks last week—Figma, Arcturus Therapeutics, and 10x Genomics—signaling selective conviction in growth equities amid broader market uncertainty.
FIGARCTTXGbiotechSaaS
GlobeNewswire Inc.GlobeNewswire Inc.··Towards Healthcare

SNP Genotyping Market Poised to Double to $19.5B by 2034

SNP genotyping market projected to grow from $8.08B (2026) to $19.48B (2034) at 11.7% annual rate, driven by personalized medicine adoption and genomic technology advances.
ILMNRHHBYTMOREGNMYGNpersonalized medicineprecision medicine